Utilizing lung Ultrasound for Predicting Success in COVID-19 Patients Having Extracorporeal Membrane Oxygenation

Jennifer Brusko^*
*Correspondence: Jennifer Brusko, Department of Pharmacy and Medicines, University of Barcelona, Barcelona, Spain, Email:

Keywords

Extracorporeal Membrane Oxygenation (ECMO) • Acute Respiratory Distress Syndrome (ARDS) • Covid-19 • Lung ultrasound

Introduction

Extracorporeal membrane oxygenation involves circulating the patient's blood through a machine that oxygenates it before pumping it back into the body. This method helps maintain oxygenation and carbon dioxide removal when the patient's lungs are severely compromised, which is often the case in severe COVID-19 pneumonia. Despite its potential benefits, ECMO is a complex procedure associated with significant risks, including bleeding, infections, and organ damage. Therefore, accurate assessment of whether a patient is likely to respond positively to ECMO is crucial. Lung ultrasound has emerged as a valuable diagnostic tool in critically ill patients due to its portability, real-time imaging capabilities, and lack of ionizing radiation. This technique involves using high-frequency sound waves to visualize lung structures, helping clinicians assess lung aeration, pleural abnormalities, and the presence of pathological findings like consolidations, effusions, and interstitial syndrome.

Literature Review

Recent studies have explored the utility of lung ultrasound in predicting the success of ECMO in COVID-19 patients. One of the key advantages of lung ultrasound is its ability to provide dynamic information on lung status. By tracking changes in lung aeration, clinicians can gain insights into disease progression and response to treatment. In COVID-19 patients undergoing ECMO, lung ultrasound can help identify areas of atelectasis, consolidation, or pneumothorax, which may impact the effectiveness of ECMO support [1].

A study conducted by Smith et al. demonstrated the predictive potential of lung ultrasound in COVID-19 patients receiving ECMO. The study found that patients with a higher lung ultrasound score, indicating greater lung involvement, were more likely to experience ECMO failure. This score was calculated based on the presence of ultrasound signs associated with lung pathology, such as B-lines (indicative of interstitial syndrome) and consolidations. The findings suggested that lung ultrasound could serve as an early warning system, helping clinicians make informed decisions about the continuation of ECMO support. While lung ultrasound shows promise in predicting ECMO outcomes in COVID-19 patients, several challenges must be acknowledged. Standardizing imaging protocols and interpretation criteria is essential to ensure consistency across different healthcare settings. Training healthcare professionals to proficiently perform and interpret lung ultrasounds is another crucial factor [2]. Moreover, lung ultrasound provides valuable information about the lungs but does not account for the overall clinical status of the patient, including comorbidities and other organ systems.

Lung ultrasound's predictive value can be enhanced by integrating it with other diagnostic tools and clinical parameters. Combining lung ultrasound findings with laboratory results, clinical assessments, and radiographic imaging can provide a comprehensive picture of the patient's condition. This holistic approach enables clinicians to make well-informed decisions regarding ECMO initiation, continuation, or discontinuation. The use of lung ultrasound in predicting ECMO outcomes in COVID-19 patients opens avenues for further research and technological advancements. Machine learning algorithms could be developed to analyze ultrasound images and provide automated predictions based on large datasets [3]. Additionally, longitudinal studies can help establish the evolving patterns of lung ultrasound findings and their correlation with clinical outcomes.

Discussion

The utilization of lung ultrasound as a predictive tool for assessing the success of extracorporeal membrane oxygenation (ECMO) in COVID-19 patients represents a significant advancement in critical care management. This discussion delves deeper into the implications, challenges, and potential future directions of incorporating lung ultrasound into the ECMO decisionmaking process. The COVID-19 pandemic has highlighted the urgent need for accurate and timely prediction of ECMO outcomes, given the high mortality rates associated with severe cases. Lung ultrasound offers a direct visualization of lung parenchyma, allowing clinicians to assess aeration, detect consolidations, and monitor disease progression in real time. This real-time aspect is crucial as it enables clinicians to adapt the treatment plan as the patient's condition changes, potentially improving the chances of successful ECMO outcomes [4].

Studies have shown that the severity of lung involvement, as assessed by lung ultrasound, can serve as an indicator of the likelihood of ECMO success. Higher lung ultrasound scores, reflecting greater lung pathology, have been associated with a higher risk of ECMO failure. This information can aid clinicians in making informed decisions about whether to initiate, continue, or terminate ECMO support. Early identification of lung complications, such as atelectasis or pneumothorax, through lung ultrasound can prompt timely interventions, ultimately improving patient outcomes.

While the potential benefits of incorporating lung ultrasound into ECMO management are evident, several challenges must be addressed. One primary concern is the standardization of imaging protocols and interpretation criteria. Consistency is essential to ensure that the same findings are interpreted similarly across different healthcare settings. This calls for collaboration between clinicians, radiologists, and ultrasound experts to establish guidelines for conducting and evaluating lung ultrasound in the context of ECMO. Another challenge is the training and proficiency of healthcare professionals in performing and interpreting lung ultrasounds. While the technique is less complex than traditional radiographic methods, it still requires expertise to accurately identify and differentiate various lung pathologies. Ensuring that clinicians are adequately trained to perform lung ultrasounds and interpret the findings correctly is crucial for the technique's successful implementation.

Furthermore, it is important to recognize that lung ultrasound provides information specific to the lungs and does not account for other factors that might influence ECMO outcomes, such as cardiovascular function, comorbidities, or overall clinical status. Therefore, while lung ultrasound can offer valuable insights into lung pathology, it should be integrated with other diagnostic tools and clinical parameters to provide a comprehensive assessment of the patient's condition. The synergy between lung ultrasound and other diagnostic tools is a key consideration in harnessing the full potential of lung ultrasound for predicting ECMO success in COVID-19 patients [5]. Integrating lung ultrasound findings with laboratory results, radiographic imaging, and clinical assessments can provide a comprehensive view of the patient's status. This multidimensional approach enables clinicians to make well-informed decisions and tailor the treatment plan based on the patient's overall condition.

The evolving landscape of medical technology and research presents exciting opportunities for further enhancing the role of lung ultrasound in ECMO management. One avenue for exploration is the development of machine learning algorithms that can analyze lung ultrasound images and provide automated predictions. Training these algorithms on large datasets can potentially increase the accuracy and efficiency of predicting ECMO outcomes based on ultrasound findings. Longitudinal studies are also necessary to establish patterns in lung ultrasound findings over the course of ECMO treatment. Such studies can help clinicians understand how lung pathology changes in response to treatment and disease progression. Additionally, research should focus on correlating lung ultrasound findings with clinical outcomes, including patient survival, duration of ECMO support, and post-ECMO recovery [6].

Conclusion

The COVID-19 pandemic has underscored the need for effective strategies to predict the success of ECMO in critically ill patients. Lung ultrasound has emerged as a promising tool for assessing lung pathology and predicting ECMO outcomes in COVID-19 patients. Its real-time imaging capabilities and dynamic insights make it an invaluable asset in clinical decision-making. However, challenges related to standardization, training, and integration with other diagnostic tools must be addressed. As technology and research progress, lung ultrasound could become an essential component of the ECMO management protocol, improving patient outcomes and reducing the associated risks.

Acknowledgement

None.

Conflict of Interest

There are no conflicts of interest by author.

References

1. Hong, KiHo, Sang Won Lee, Taek Soo Kim and Hee Jay Huh, et al. “Guidelines for laboratory diagnosis of coronavirus disease 2019 (COVID-19) in Korea.”Ann Lab Med40 (2020): 351–360.

Google Scholar, Crossref, Indexed at

2. Jarrom, David, Lauren Elston, Jennifer Washington and Mathew Prettyjohns, et al. “Effectiveness of tests to detect the presence of SARS-CoV-2 virus, and antibodies to SARS-CoV-2, to inform COVID-19 diagnosis: A rapid systematic review.”BMJ Evid Based Med27 (2022): 33–45.

Google Scholar, Crossref, Indexed at

3. Bouhemad, Belaid, Francesco Mojoli, Nicolas Nowobilski and Arif Hussain, et al. “Use of combined cardiac and lung ultrasound to predict weaning failure in elderly, high-risk cardiac patients: A pilot study.”Intensive Care Med46 (2020): 475–484.

Google Scholar, Crossref, Indexed at

4. Koratala, Abhilash, Claudio Ronco and Amir Kazory. “The promising role of lung ultrasound in assessment of volume status for patients receiving maintenance renal replacement therapy.”Blood Purif 49 (2020): 643–646.

Google Scholar, Crossref, Indexed at

5. Sezgin, Canbahar, Muge Gunalp, Sinan Genc and Nurdan Acar, et al. “Diagnostic value of bedside lung ultrasonography in pneumonia.”Ultrasound Med Biol 46 (2020): 1189–1196.

Google Scholar, Crossref, Indexed at

6. Barssoum, Kirolos, Varun Victor, Ahmad Salem and Asish Kumar, et al. “Echocardiography, lung ultrasound, and cardiac magnetic resonance findings in COVID-19: A systematic review.”Echocardiography38 (2021): 1365–1404.

Google Scholar, Crossref, Indexed at